FFA
BMRN icon

First Foundation Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

First Foundation Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-8,505
Closed -$773K – 313
2017
Q2 		$773K Buy
8,505
+195
+2% +$17.7K 0.05% 175
2017
Q1 		$729K Buy
8,310
+1,760
+27% +$157K 0.05% 168
2016
Q4 		$543K Hold
6,550
– – 0.04% 193
2016
Q3 		$606K Hold
6,550
– – 0.04% 176
2016
Q2 		$510K Buy
6,550
+1,900
+41% +$162K 0.04% 189
2016
Q1 		$384K Buy
+4,650
New +$378K 0.03% 201

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

First Foundation Advisors's BMRN Position: Q3 2017 in Review

First Foundation Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2017, closing a stake of 8,505 shares — an estimated $773K sold.

First Foundation Advisors first reported a position in BMRN in Q1 2016 and held it in 6 quarters. The position peaked at $773K in Q2 2017. 411 funds tracked by Wall St. Rank hold BMRN as of Q3 2017.

  • First Foundation Advisors reported no remaining BioMarin Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • First Foundation Advisors sold 8,505 BioMarin Pharmaceuticals shares in Q3 2017, an estimated $773K.
  • First Foundation Advisors first reported a position in BioMarin Pharmaceuticals in Q1 2016 and held it in 6 quarters.
  • First Foundation Advisors's BioMarin Pharmaceuticals position peaked at $773K in Q2 2017.
  • 411 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2017.

Based on First Foundation Advisors's 13F filing for Q3 2017, filed 14 Nov 2017.